Zolgensma® continues to set new pricing precedents for gene therapies in Europe and Japan
The new gene therapy Zolgensma® recently received the highest ever reimbursement price in Japan and the conditional EMA approval is...
top of page
Never miss an update, subscribe today.
​
RJW&partners will only use your personal information to administer your account and provide the products and services you request. You can unsubscribe at any time, to do so please review our Privacy Policy. By clicking subscribe, you consent to allow RJW&partners to store and process your personal information.
bottom of page